Minimizing Risk And Maximizing Efficiency By Taking A Strategic Approach To Comparative Trial Supply
Widely acknowledged to be a prerequisite for formulary listing and even successful licensure, comparator drugs and co-therapies are used within an estimated two-thirds of clinical trials. Nicholas Griffin at Almac Clinical Services evaluates how to minimize risk and increase efficiency when taking a strategic approach to comparative trial supply.
